Related references
Note: Only part of the references are listed.Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?
Rafael Zaragoza et al.
Therapeutics and Clinical Risk Management (2016)
Kinetic Patterns of Candida albicans Germ Tube Antibody in Critically Ill Patients: Influence on Mortality
Rafael Zaragoza et al.
CLINICAL AND VACCINE IMMUNOLOGY (2009)
Clinical significance of the detection of Candida albicans germ tube-specific antibodies in critically ill patients
R. Zaragoza et al.
CLINICAL MICROBIOLOGY AND INFECTION (2009)
Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections
Michael D. Parkins et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Anidulafungin versus fluconazole for invasive candidiasis
Annette C. Reboli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
Ernst-Ruediger Kuse et al.
LANCET (2007)
Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting
L. Ostrosky-Zeichner et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2007)
Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study
Kevin W. Garey et al.
CLINICAL INFECTIOUS DISEASES (2006)
A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis
J Pachl et al.
CLINICAL INFECTIOUS DISEASES (2006)
A bedside scoring system (Candida score'') for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization
C León et al.
CRITICAL CARE MEDICINE (2006)
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial
BJ Kullberg et al.
LANCET (2005)
Multicenter clinical evaluation of the (1→3) β-D-glucan assay as an aid to diagnosis of fungal infections in humans
L Ostrosky-Zeichner et al.
CLINICAL INFECTIOUS DISEASES (2005)
Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained:: a potential risk factor for hospital mortality
M Morrell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials
NI Paphitou et al.
MEDICAL MYCOLOGY (2005)
Early diagnosis of candidiasis in non-neutropenic critically ill patients
J Ibàñez-Nolla et al.
JOURNAL OF INFECTION (2004)
Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients
R Piarroux et al.
CRITICAL CARE MEDICINE (2004)
Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis
J Garnacho-Montero et al.
CRITICAL CARE MEDICINE (2003)
Management of candida species infections in critically ill patients
P Eggimann et al.
LANCET INFECTIOUS DISEASES (2003)
Comparison of caspofungin and amphotericin B for invasive candidiasis.
J Mora-Duarte et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy
M Kami et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Contribution of serological tests and blood culture to the early diagnosis of systemic candidiasis
H Yera et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2001)
Share Paper
